<!DOCTYPE html>
<html>
<head>
  <meta charset="utf-8">
  <title>Regeneron Advances Allergy Pipeline with Two Positive Phase 3 Trials Evaluating First-in-Class Antibody-Blockers of Cat and Birch Allergies</title>
</head>
<body>
  <a href="../../index.html">← Back to home</a>
  <h1>Regeneron Advances Allergy Pipeline with Two Positive Phase 3 Trials Evaluating First-in-Class Antibody-Blockers of Cat and Birch Allergies</h1>
  <ul>
<li>May 2024.</li>
<li>08, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc.</li>
<li>Additional Phase 3 development is planned to begin in the first half of 2026.</li>
<li>About 35% of patients continue to experience moderate to severe symptoms despite standard of care therapy.</li>
<li>Itch was reduced by 52% (p&lt;0.0001), conjunctival redness by 39% (p&lt;0.0001) and skin prick reactivity by 44% (p&lt;0.0001).</li>
<li>Itch was reduced by 51% (p&lt;0.0001), conjunctival redness by 46% (p&lt;0.0001), and skin prick reactivity by 44% (p&lt;0.0001).</li>
<li>In addition, REGEN-COV® (casirivimab and imdevimab) had been authorized by the FDA during the COVID-19 pandemic until 2024.</li>
</ul>
<p><a href="https://finance.yahoo.com/news/regeneron-advances-allergy-pipeline-two-103000615.html">Source</a> · 2025-09-08T10:30:00+00:00</p>
</body>
</html>